Research programme: infectious disease diagnostics - Molecular Insight Pharmaceuticals/Syracuse UniversityAlternative Names: MIP 160; Tc 99m-labeled chemotactic peptide
Latest Information Update: 25 Mar 2008
At a glance
- Originator Molecular Insight Pharmaceuticals; Syracuse University
- Class Imaging agents; Radiopharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Infections
Most Recent Events
- 21 Oct 2003 Preclinical trials in Diagnostic imaging of Infections in USA (unspecified route)